Insight

Michael Chuong Highlighted Phase 3 PANOVA-3 Trial on TTFields in Locally Advanced Pancreatic Cancer

Michael Chuong/mapquest.com

Jun 22, 2025, 10:42

Michael Chuong Highlighted Phase 3 PANOVA-3 Trial on TTFields in Locally Advanced Pancreatic Cancer

Michael Chuong, Vice Chair and Medical Director of the Department of Radiation Oncology at Miami Cancer Institute, shared a post on LinkedIn:

“The phase 3 PANOVA-3 trial that was recently published in Journal of Clinical Oncology showed that TTFields improves OS, distant PFS, and pain-free survival over GnP alone for locally advanced pancreatic cancer, and should be a new standard of care option.

Local PFS in both arms, however, was suboptimal and therefore the natural question to answer next is whether definitive radiation therapy (which was not included in the trial design, but is standard of care at many institutions) would further improve outcomes.

We are enrolling non-metastatic locally advanced pancreatic cancer patients after at least 3 months of induction FFX and/or GnP to a single arm phase 2 trial of ablative MR-guided SBRT (50 Gy in 5 fractions) with concurrent and maintenance TTFields.

Around 75-80% of patients will develop distant metastases within 2 years after chemotherapy + radiation therapy, routinely in the liver and peritoneum, and the study hypothesis is that TTFields will delay distant progression. We have a signal from PANOVA-3 that this is in fact the mechanism by which TTFields provides benefit (post-hoc analysis), which seemingly may translate into improved OS.

Perhaps the optimal regimen for patients with unresectable locally advanced pancreatic cancer will one day be “trimodality therapy” of induction chemo + TTFields + ablative radiation?”

Title: Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study

Journal: JCO

Authors: Hani M Babiker, Vincent Picozzi, Sreenivasa R Chandana, Bohuslav Melichar, Anup Kasi, Jin Gang, Javier Gallego, Andrea Bullock, Hao Chunyi, Lucjan Wyrwicz, Erika Hitre, Arsen Osipov, Christelle de la Fouchardiere, Inmaculada Ales, Tomislav Dragovich, Woojin Lee, Kynan Feeney, Philip Philip, Makoto Ueno, Eric Van Cutsem, Thomas Seufferlein, Teresa Macarulla

Read the full article.

TTFields

More posts featuring Michael Chuong on OncoDaily.

Andrea Bullock Anup Kasi Arsen Osipov Bohuslav Melichar cancer CHRISTELLE DE LA FOUCHARDIERE Eric van Cutsem Erika Hitre Gemcitabine Hani M. Babiker Hao Chunyi Inmaculada Ales Javier Gallego JCO Jin Gang Journal of Clinical Oncology Kynan Feeney Lucjan Wyrwicz Makoto Ueno Miami Cancer Institute Michael Chuong nab-paclitaxel OncoDaily Oncology pancreatic adenocarcinoma PANOVA-3 PANOVA-3 trial Philip Philip Sreenivasa R. Chandana Teresa Macarulla Thomas Seufferlein Tomislav Dragovich Vincent Picozzi Woojin Lee

Cancer in Dogs: Common Types, Symptoms, Diagnosis, and Treatment

Cardio-Oncology in Focus: How Chemotherapy Can Harm Heart Health

Oncologist Near Me – Razelle Kurzrock: Revolutionizing Cancer Treatment Through Precision Medicine

Smoking and Bladder Cancer: What You Need to Know to Protect Yourself

Cervical Cancer Screening: Who Needs a Pap Smear or HPV Test and When?